Wells Fargo upgrades Humana to Overweight, raises target to $502

0 min read | Published on 10 Jul 2026, 01:55 AM |Updated on 13 Jul 2026, 06:35 PM

Reviewed by

Radhika SScanX News Team

Key Highlights

Wells Fargo analyst Stephen Baxter upgraded Humana from Equal-Weight to Overweight, raising the price target to $502 from $227, signaling a bullish outlook.

*this image is generated using AI for illustrative purposes only.

Wells Fargo analyst Stephen Baxter has upgraded Humana (NYSE: HUM) from Equal-Weight to Overweight, significantly raising the price target to $502 from the previous $227. This revision signals a more bullish outlook on the healthcare insurer's future performance and intrinsic value compared to sector peers.

The upgrade to Overweight suggests that the stock is now expected to outperform the broader market or sector averages. The substantial increase in the price target reflects a shift in the analyst's financial model, likely driven by revised expectations regarding the company's earnings potential.

Rating and Target Details

The following table outlines the changes made by Wells Fargo:

Metric	Previous Value	New Value
Rating	Equal-Weight	Overweight
Price Target	$227	$502

This move comes as investors and analysts continue to evaluate Humana's position within the healthcare sector. The raised price target and rating upgrade indicate a more optimistic view of the company's growth prospects.

What specific factors in Humana's financial model drove the substantial increase in the price target?

How might this upgrade influence other analysts' ratings and price targets for Humana?

What are the potential risks to Humana's growth prospects that could impact the new price target?

Cantor Fitzgerald raises Humana price target to $300

0 min read | Published on 07 Jul 2026, 06:48 PM |Updated on 07 Jul 2026, 06:48 PM

Reviewed by

Radhika SScanX News Team

Add as a preferred
source on Google

Key Highlights

Cantor Fitzgerald analyst Sarah James maintains a Neutral rating on Humana (NYSE: HUM) and raises the price target to $300 from $264, reflecting a revised valuation outlook.

*this image is generated using AI for illustrative purposes only.

Cantor Fitzgerald analyst Sarah James has maintained a Neutral rating on Humana (NYSE: HUM) while raising the price target to $300 from $264. The revised target indicates a higher valuation expectation despite the unchanged stance on the stock's performance potential.

The decision to increase the price target suggests an updated assessment of Humana's financial position or market conditions. However, the Neutral rating implies that the analyst does not see sufficient catalysts for a Buy recommendation at this time.

The following table outlines the revised rating details:

Metric	Value
Rating	Neutral
Previous Price Target	$264
New Price Target	$300

Investors will monitor Humana's upcoming earnings reports and strategic developments for further clarity on the company's trajectory. The current rating balances the raised price target with a cautious outlook on near-term growth drivers.

What specific factors could shift Humana's rating from Neutral to Buy in the coming quarters?

How might changes in Medicare Advantage reimbursement rates impact Humana's future profitability?

What strategic developments is Humana pursuing to drive growth beyond its current valuation?